

FINANCIAL DISCLOSURE REPORT INITIAL FILING

Report Required by the Ethics
in Government Act of 1978
(5 U.S.C. app. §§ 101-111)

1. Person Reporting (last name, first, middle initial) Ray, J. Thomas	2. Court or Organization U. S. District Court - ED AR	3. Date of Report 05/3/2018
4. Title (Article III judges indicate active or senior status; magistrate judges indicate full- or part-time) U. S. Magis. Judge - Full Time	5a. Report Type (check appropriate type) ☐ Nomination ☐ Date ☒ Initial ☐ Annual ☐ Final 5b. ☐ Amended Report	6. Reporting Period 01/01/2017 to 12/31/2017
7. Chambers or Office Address Richard Sheppard Arnold United States Courthouse 500 West Capitol, Room D 144 Little Rock, AR 72201		
IMPORTANT NOTES: The instructions accompanying this form must be followed. Complete all parts, checking the NONE box for each part where you have no reportable information.		

I. POSITIONS. (Reporting individual only; see pp. 9-13 of filing instructions.)

☐ NONE (No reportable positions.)

	<u>POSITION</u>	<u>NAME OF ORGANIZATION/ENTITY</u>
1.	Trustee	Rollover IRA
2.	Trustee	IRA #1
3.	Trustee	Inherited IRA
4.	Trustee	IRA #2
5.		

II. AGREEMENTS. (Reporting individual only; see pp. 14-16 of filing instructions.)

☒ NONE (No reportable agreements.)

	<u>DATE</u>	<u>PARTIES AND TERMS</u>
1.		
2.		
3.		

FINANCIAL DISCLOSURE REPORT

Page 2 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

III. NON-INVESTMENT INCOME. *(Reporting individual and spouse; see pp. 17-24 of filing instructions.)***A. Filer's Non-Investment Income**NONE *(No reportable non-investment income.)*DATESOURCE AND TYPEINCOME
(yours, not spouse's)

1. _____

2. _____

3. _____

4. _____

B. Spouse's Non-Investment Income - *If you were married during any portion of the reporting year, complete this section.**(Dollar amount not required except for honoraria.)*NONE *(No reportable non-investment income.)*DATESOURCE AND TYPE

1. _____

2. _____

3. _____

4. _____

IV. REIMBURSEMENTS *— transportation, lodging, food, entertainment.**(Includes those to spouse and dependent children; see pp. 25-27 of filing instructions.)*NONE *(No reportable reimbursements.)*SOURCEDATESLOCATIONPURPOSEITEMS PAID OR PROVIDED

1. _____

2. _____

3. _____

4. _____

5. _____

FINANCIAL DISCLOSURE REPORT

Page 3 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

V. GIFTS. *(Includes those to spouse and dependent children; see pp. 28-31 of filing instructions.)*NONE *(No reportable gifts.)*

<u>SOURCE</u>	<u>DESCRIPTION</u>	<u>VALUE</u>
1.		
2.		
3.		
4.		
5.		

VI. LIABILITIES. *(Includes those of spouse and dependent children; see pp. 32-33 of filing instructions.)*NONE *(No reportable liabilities.)*

<u>CREDITOR</u>	<u>DESCRIPTION</u>	<u>VALUE CODE</u>
1.		
2.		
3.		
4.		
5.		

FINANCIAL DISCLOSURE REPORT

Page 4 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
1. Abbvie C.S.	A	Dividend	K	T					
2. Acadia C.S.		None	K	T					
3. Agios C.S.		None			Buy	05/31/17	K		
4. Allergan C.S.	C	Dividend	N	T	Buy	10/31/17	L		
5. Amgen	B	Dividend	L	T					
6. Bank of America C.S.	A	Dividend	L	T					
7. Berkshire Hathaway (B) C.S.		None	M	T					
8. Biomarin C.S.		None	K	T	Buy	08/11/17	K		
9. Biogen C.S.		None			Sold	07/07/17	L	D	
10. Bristol Meyers C.S.	A	Dividend	K	T					
11. Celgene C.S.		None	M	T					
12. Chevron C.S.	D	Dividend	M	T					
13. Conoco Phillips C.S.	C	Dividend	M	T					
14. Eli Lilly C.S.	D	Dividend	N	T					
15. Encana Corp. C.S.	A	Dividend			Sold	01/06/17	J	B	
16. Enterprise Products C.S.	D	Dividend	L	T	Buy (add'l)	10/25/17	K		
17. Exxon Mobil Corp. C.S.	D	Dividend	N	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 5 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

18. Freeport McMoran C.S.		None			Sold	01/06/17	J		
19. Gilead, C.S.	D	Dividend	N	T					
20. Incyte, C.S.		None	K	T	Buy	11/20/17	K		
21. Intel C.S.	B	Dividend	L	T					
22. J P Morgan Chase C.S.	B	Dividend	L	T					
23. Johnson & Johnson C.S.	D	Dividend	N	T					
24. Merck & Co. Inc. C.S.	D	Dividend	N	T					
25. Permian Basin Trust C.S.	A	Dividend			Sold	11/07/17	J		
26. Pfizer Inc. C.S.	C	Dividend	M	T					
27. Phillips 66 C.S.	C	Dividend	M	T					
28. Phillips 66 Partners C.S.	C	Dividend	L	T					
29. Roche ADR	A	Dividend			Sold	07/12/17	K	A	
30. Regeneron Inc.		None	M	T					
31. Sanofi Aventis C.S.	C	Dividend	L	T					
32. Seattle Genetics, Inc. C.S.		None			Sold	02/13/17	K	E	
33. Stryker Corp. C.S.	A	Dividend			Sold	07/07/17	K	E	
34. Valero Energy C.S.	D	Dividend	M	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 6 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

35. Wells Fargo C.S.	B	Dividend	L	T					
36. Charles Schwab Money Market (Cash Equivalents)	A	Interest	L	T					
37.									
38. ORI/Acadia & Ver. Par., LA; McGowan Inc.; Zachry Exploration	F	Royalty	N	W					
39. ORI/Regan County, TX/Pioneer Natural Resources	A	Royalty	L	W					
40. W/I; Acadia & Vermillion Par., LA; McGowan Inc.	E	Royalty	N	W					
41. ORI/Acadia Par., LA; Zachry Eploraton	D	Royalty	N	W					
42. Rental Property (Pulaski County, AR)	A	Rent	N	W					
43.									
44. Rollover IRA									
45. Charles Schwab Money Market (Cash Equivalents)	A	Interest	K	T					
46. - Acadia Pharmaceuticals C.S.		None	K	T					
47. - Agios C.S.		None			Buy	05/31/17	K		
48. Allergan C.S.	C	Dividend	N	T					
49. - Amgen C.S.	C	Dividend	M	T					
50. - Bank of America. C.S.	A	Dividend	K	T					
51. - Berkshire Hathaway (B) C.S.		None	M	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 7 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
52. - Biogen C.S.		None			Sold	03/09/17	L	D	
53. - Celgene C.S.		None	M	T					
54. - Chevron C.S.	B	Dividend	L	T					
55. - Conoco Phillips C.S.	B	Dividend	L	T					
56. - Enterprise Prod. Partners	B	Dividend	L	T	Buy	11/24/17	L		
57. - Exxon C.S.	C	Dividend	L	T					
58. - Gilead Sciences Inc. C.S.	C	Dividend	M	T					
59. - Incyte C.S.		None	K	T	Buy	11/24/17	K		
60. - J.P. Morgan C.S.	B	Dividend	L	T					
61. - Johnson & Johnson C.S.	C	Dividend	L	T					
62. - Kinder Morgan Inc. C.S.	A	Dividend			Sold	09/18/17	K		
63. - Merck & Co. Inc. C.S.	B	Dividend	L	T					
64. - Pfizer Inc. C.S.	D	Dividend	M	T	Sold (part)	07/28/17	K	C	
65. - Phillips 66 C.S.	B	Dividend	L	T					
66. - Phillips 66 Partners L.P.	A	Dividend	K	T					
67. - Regeneron C.S.		None	M	T	Buy (add'l)	11/28/17	K		
68. - Roche Hldg ADR	A	Dividend			Sold	02/17/17	K	A	

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	L = \$50,001 - \$100,000 M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 8 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
69. - Sanofi Aventis C.S.	B	Dividend	K	T					
70. - Stemline Therapeutics C.S.		None	K	T					
71. - Whiting Petroleum C.S.		None			Sold (part)	11/03/17	J	B	
72.									
73. IRA #1									
74. - Abbvie C.S.	A	Dividend	J	T					
75. - Acadia Pharm. C.S.		None	J	T					
76. - Allergan C.S.	A	Dividend	K	T					
77. - Amgen Inc. C.S.	A	Dividend	K	T					
78. - Berkshire Hathaway (B) C.S.		None	K	T					
79. - Biogen C.S.			J	T	Buy	08/17/17	J		
80. - Celgene C.S.		None	L	T					
81. - Conoco C.S.	A	Dividend	J	T					
82. - Exxon Mobil C.S.	A	Dividend	J	T					
83. - Freeport McMoran		None			Sold	07/07/17	J		
84. - Gilead Sciences Inc. C.S.	A	Dividend	K	T					
85. - Johnson & Johnson C.S.	A	Dividend	K	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 9 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
86. - J.P. Morgan Chase C.S.	A	Dividend	J	T					
87. - Merck C.S.	A	Dividend	K	T					
88. - Phillips 66 C.S.	A	Dividend			Sold	07/28/17	J	D	
89. - Pfizer C.S.	A	Dividend	K	T					
90. - Stemline Therapeutics C.S.		None			Sold	07/07/17	J		
91. - Charles Schwab Money Market (Cash Equivalents)	A	Interest	J	T					
92.									
93. Inherited IRA									
94. - AbbVie Inc. C.S.	A	Dividend	J	T					
95. - Acadia Pharm. C.S.		None	J	T					
96. - Agios C.S.		None	J	T					
97. - Allergan C.S.	A	Dividend	K	T					
98. - Berkshire Hathaway C.S.		None	K	T					
99. - Biogen Inc. C.S.		None			Sold	07/07/17	K	A	
100. - Celgene C.S.		None	J	T					
101. - Chevron C.S.	A	Dividend	J	T					
102. - Conoco Phillips C.S.	A	Dividend	J	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 10 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

103. - Gilead Science Inc. C.S.	A	Dividend	K	T					
104. - Johnson & Johnson C.S.	A	Dividend	J	T					
105. - Merck C.S.	A	Dividend	J	T					
106. - Pfizer C.S.	A	Dividend	J	T					
107. - Proctor & Gamble C.S.	A	Dividend	J	T					
108. - Wells Fargo & Co. C.S.	A	Dividend	J	T					
109. - Whiting Petroleum C.S.		None	J	T					
110. - Matthews Pacific Tiger M.F.	A	Dividend			Sold	07/07/17	J	A	
111. - Preimcap Odyssey Stock M.F.	A	Dividend			Sold	07/07/17	J	B	
112. - T. Rowe Price Overseas M.F.	A	Dividend			Sold	07/07/17	J	A	
113. - Charles Schwab Money Market (Cash Equivalents)	A	Interest	J	T					
114.									
115.									
116. IRA #2									
117. - Allergan C.S.	A	Dividend	K	T					
118. - Amgen Inc. C.S.	A	Dividend	K	T					
119. - Bank of America C.S.	A	Dividend	J	T					

1. Income Gain Codes: (See Columns B1 and D4)	A ~\$1,000 or less F ~\$50,001 - \$100,000	B ~\$1,001 - \$2,500 G ~\$100,001 - \$1,000,000	C ~\$2,501 - \$5,000 H1 ~\$1,000,001 - \$5,000,000	D ~\$5,001 - \$15,000 H2 ~More than \$5,000,000	E ~\$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J ~\$15,000 or less N ~\$250,001 - \$500,000 P3 ~\$25,000,001 - \$50,000,000	K ~\$15,001 - \$50,000 O ~\$500,001 - \$1,000,000	L ~\$50,001 - \$100,000 P1 ~\$1,000,001 - \$5,000,000 P4 ~More than \$50,000,000	M ~\$100,001 - \$250,000 P2 ~\$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 11 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

120. - Berkshire Hathaway (B) C.S.		None	K	T					
121. - Celgene C.S.		None	L	T					
122. - Conoco C.S.	A	Dividend			Sold	10/06/17	J	B	
123. - Exxon C.S.	A	Dividend	J	T					
124. - Gilead Sciences Inc. C.S.	A	Dividend	K	T					
125. - Johnson & Johnson C.S.	A	Dividend	K	T					
126. - Merck C.S.	A	Dividend	K	T					
127. - Pfizer Inc. C.S.	A	Dividend	K	T					
128. - Charles Schwab Money Market (Cash Equivalents)	A	Interest	J	T					
129.									

1. Income Gain Codes:	A = \$1,000 or less	B = \$1,001 - \$2,500	C = \$2,501 - \$5,000	D = \$5,001 - \$15,000	E = \$15,001 - \$50,000
(See Columns B1 and D4)	F = \$50,001 - \$100,000	G = \$100,001 - \$1,000,000	H1 = \$1,000,001 - \$5,000,000	H2 = More than \$5,000,000	
2. Value Codes	J = \$15,000 or less	K = \$15,001 - \$50,000	L = \$50,001 - \$100,000	M = \$100,001 - \$250,000	
(See Columns C1 and D3)	N = \$250,001 - \$500,000	O = \$500,001 - \$1,000,000	P1 = \$1,000,001 - \$5,000,000	P2 = \$5,000,001 - \$25,000,000	
	P3 = \$25,000,001 - \$50,000,000		P4 = More than \$50,000,000		
3. Value Method Codes	Q = Appraisal	R = Cost (Real Estate Only)	S = Assessment	T = Cash Market	
(See Column C2)	U = Book Value	V = Other	W = Estimated		

Name of Person Reporting	Date of Report
Ray, J. Thomas	05/3/2018

VIII. ADDITIONAL INFORMATION OR EXPLANATIONS. *(Indicate part of report.)*

FINANCIAL DISCLOSURE REPORT

Page 13 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

05/3/2018

IX. CERTIFICATION.

I certify that all information given above (including information pertaining to my spouse and minor or dependent children, if any) is accurate, true, and complete to the best of my knowledge and belief, and that any information not reported was withheld because it met applicable statutory provisions permitting non-disclosure.

I further certify that earned income from outside employment and honoraria and the acceptance of gifts which have been reported are in compliance with the provisions of 5 U.S.C. app. § 501 et. seq., 5 U.S.C. § 7353, and Judicial Conference regulations.

Signature: s/ **J. Thomas Ray**

NOTE: ANY INDIVIDUAL WHO KNOWINGLY AND WILLFULLY FALSIFIES OR FAILS TO FILE THIS REPORT MAY BE SUBJECT TO CIVIL AND CRIMINAL SANCTIONS (5 U.S.C. app. § 104)

Committee on Financial Disclosure
Administrative Office of the United States Courts
Suite 2-301
One Columbus Circle, N.E.
Washington, D.C. 20544